### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### FORM 8-K

### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2023

OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-38242

(Commission File Number)

26-1761833

(I.R.S. Employer Identification Number)

2850 Frontier Drive Warsaw, Indiana (Address of principal executive offices)

46582 (Zip Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.00025 par value per share	KIDS	Nasdaq Global Market

Registrant's telephone number, including area code: (574) 268-6379 Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act 🗆

### Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

### Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits	
	Exhibit No.	Description
	<u>99.1</u>	Orthopediatrics Corp. Investor Presentation dated May 2023
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

\* \* \* \* \* \*

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OrthoPediatrics Corp.

Date: May 16, 2023

By:

/s/ Daniel J. Gerritzen Daniel J. Gerritzen, General Counsel and Secretary

- 2 -




### Disclaimer

Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, are forward-looking statements. You can often identify forward-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "interving "report," "angot," "pinging," "pin," "picettial," "project, "should," "will or "word-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "interving "ropoing," "pin," "picettial," "project," "should," "will or "word-looking statements by words such as "anticipate," "believe," statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID 19 and respiratory syncytial virus, that may cause our result, statevity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID 19 and respiratory syncytial virus, that may cause our results, the time of the development and to develop and commercial activatements. Forward-looking statements have include, among other things, statewiths relating to: our ability to achieve or sustain profitability in the future; our ability to antinian and expand our network of third-party independent sales agencies and distribute our products; and our ability to maintain and expand our network of third-party independent sales agencies and distribute our products; and our ability to printing and the materially from the plans, intentions and expectations to marker and espectations to marker and espectations the respiratory transpiratements. Avail and expectation and expend and or network for the plans, intentions and expectations expressed

### Use of Non-GAAP Financial Me

Use of Non-GAAP Financial Measures
This presentation includes certain non-GAAP financial measures such as organic revenue, adjusted diluted earnings (loss) per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with
U.S. generally accepted accounting principies (GAAP). Sales excludes from our reported net revenue growth the impacts of revenue from any acquired business that have been owned for less than
one year. We believe that providing the non-GAAP organic revenue is useful as a way to measure and evaluate our underlying performance consistently across the periods presented. Adjusted earnings (loss) per share in
this presentation represents diluted earnings (loss) per share in a GAAP basis, plus the accreted interest attributable to acquisition instalment payabies, the far value adjustment of contingent consideration is associated with our
estimates of the value of earn-outs in connection with certain acquisitions and the non-recurring professional fees, accrued legal settlement costs and minimum purchase commitment costs. The fair value adjustment of contingent consideration is associated with our
estimates of the value of earn-outs in connection with certain acquisitions and the non-recurring professional fees, accrued legal settlement costs, and minimum purchase commitments. The Company believes the non-GAAP measures
provided in this erelases enable it to further and more consistently analyzes the period-operiod financial performance of its combines to payability. Adjusted EBITDA is anno-GAAP financial measure and should not be considered aparties to evalue companies in its industry. Adjusted EBITDA is anno-GAAP financial measure and should not be considered aparties to evalue companies in its industry. Adjusted EBITDA is a non-GAAP financial measure and should not be considered aparties to evalue companies that cost of minimum purchase commitments. The Company believes the pro-set income taxes (loss in non-faAP financial performance or ashore financial performance or


2023 // Investor Presentation




2023 // Investor Presentation
 Indudes patients treated by MD Orthopaedics (MDO) as well as Pega Medical since inc


~ 650,000 pediatric patients treated since inception<sup>1</sup>


OrthOPediatrics"


























### 04 Expand Market with M&A

### **MD Orthopaedics**

- Develops, manufactures and sells the patented Mitchell Ponseti Ankle-Foot Orthosis (AFO) to treat clubfoot
- Dr. Ignacio Ponseti developed the gold standard for treating clubfoot which has >90% success rate
- Casting is used from 0-3mos then bracing from 3mos-4 years. Requires multiple sizes as child grows creating repeat revenue.
- Products sold in 90 countries including e-commerce platform direct to consumers
- Approximately 80% of a pediatric surgeon's treatment time is non-surgical
- Creates a profitable platform business for OP to develop and manufacture best-in-class specialty bracing with speed to market (class 1 device) as well as no consignment inventory required to grow the business

### Terms:

- Closed April 1, 2022
- \$8.2M cash, \$8.9M shares, \$2.5M RSA
  - 2023 // Investor Presentation

# <section-header><section-header><image><image><image>

### Acquired Innovative Technologies -

### **Pega Medical**

- Developed the Fassier-Duval Telescopic Intramedullary Nail System (FD Nail)
- FD Nail is cutting-edge implant designed to treat bone deformities in children with Osteogenesis Imperfecta without disrupting their normal growth
- Pega offers 7 products in total, 6 of which focus on limb deformity correction, and 1 trauma
- Products sold in 70 countries including e-commerce platform direct to consumers
- Approximately 35,000 children suffer from Osteogenesis Imperfecta in the U.S.

2023 // Investor Presentation

### Terms:

- Closed July 5, 2022
- \$31M cash, \$2M stock



# Pega Medical

Fassier-Duval Telesc System The name

Telescopic IM System<sup>TM</sup> The nail that grows with your patient!





### 04 Expand Market with M&A

### Orthex

- Disruptive software complements ex-fix frame
- Expands addressable market
- Serve 85% of procedures, up from 65%
  Significantly simplifies surgical planning and alignment
- Enables participation in most complex surgeries

### ApiFix

- Disruptive non-fusion technology
- Viable alternative to failed bracing & spinal fusion

2023 // Investor Presentation

- Posterior, minimally invasive approach
- Motion preserving capabilities
- Granted FDA HDE approval









PrthoPediatrics 16 -

### Acquired Innovative Technologies


- Acquired software-based and non-fusion
- Acquired software
   technologies
- Significant sales synergies with legacy portfolio
- Expands critical KOL network
- Provides surgeons broadest product portfolio



















(\$ in Millions)						
	FY 2020	FY 2021	FY2022	1Q 2023	1Q 2022	
Revenue	\$71.1	\$98.0	\$122.3	\$31.6	\$23.4	
Growth %	(2%)	38%	25%	35%	9%	
Gross profit	\$55.0	\$73.4	\$90.7	\$23.6	\$18.6	
Margin %	77%	75%	74%	75%	79%	
Operating expenses	\$81.8	\$91.4	\$116.1	\$32.2	\$25.0	
Operating loss	(\$26.8)	(\$18.0)	(\$25.4)	(\$8.6)	(\$6.4)	
Net (loss) income	(\$32.9)	(\$16.2)	\$1.3	(\$6.8)	(\$9.1)	
EPS <sup>1</sup>	(\$1.82)	(\$0.84)	\$0.06	(\$0.30)	(\$0.47)	
					~	

### (\$ in Millions)

### **Organic Revenue Reconciliation**

		ths Ended h 31,			nths Ended ch 31,
Product Sales by geography	2023	2022	Product Sales by category	2023	2022
As reported:			As reported:		2
U.S.	\$23.8	\$18.2	Trauma and deformity	\$23.4	\$16.5
0.3.	\$25.0	\$10.2	Scoliosis	\$7.1	\$6.0
International	\$7.8	\$5.2	Sports medicine/other	\$1.1	\$0.9
Less impact from acquisitions:			Less: impact from acquisitions		
U.S.	\$2.6	-	Trauma and deformity	\$4.9	-
0.3.	\$2.0	-	Scoliosis	-	-
International	\$2.3	-	Sports medicine/other	-	-
Organic revenue:			Organic revenue:		
U.S.	\$21.2	\$18.2	Trauma and Deformity	\$18.6	\$16.5
0.3.	\$21.2	\$10.2	Scoliosis	\$7.1	\$6.0
International	\$5.5	\$5.2	Sports medicine/other	\$1.1	\$0.9
Total Organic Revenue	\$26.8	\$23.4	Total Organic Revenue	\$26.8	\$23.4

### (\$ in Millions)

## Adjusted EBITDA Reconciliation

		ths Ended h 31,
	2023	2022
Net income (loss)	(\$6.8)	(\$9.1)
Interest expense, net	(0.2)	0.6
Other income (expense)	(0.3)	(0.1)
Provision for income tax (benefit)	(0.6)	(0.3)
Depreciation and amortization	3.8	3.0
Stock-based compensation	2.1	1.5
Fair value adjustment of contingent consideration	(0.7)	2.6
Acquisition related costs	-	0.2
Nonrecurring Pega conversion fees	0.3	-
Minimum purchase commitment cost	0.3	0.1
Adjusted EBITDA	(\$2.1)	(\$1.6)

2023 // Investor Presentation

Ortho Pediatrice 27

## Adjusted EPS Reconciliation

	and the second	nths Ended ch 31,
	2023	2022
Earnings (loss) per share, diluted (GAAP)	(\$0.30)	(\$0.47)
Accretion of interest attributable to acquisition installment payable	0.02	0.02
Fair value adjustment of contingent consideration	(0.03)	0.13
Acquisition related costs	-	0.01
Nonrecurring Pega conversion fees	0.01	-
Minimum purchase commitment cost	0.01	0.01
Earnings (loss) per share, diluted (non-GAAP)	(\$0.29)	(\$0.30)

- 2023 // Investor Presentation

PrthoPediatrice 28 -

### (\$ in Millions) As of March 31, 2023

Assets	
Cash & short-term investments	109.2
Account receivable	26.8
Inventory (net)	84.9
Other current assets	4.0
Total Current Assets	225.0
PP&E (net)	36.9
Intangibles and goodwill	164.4
Total Assets	426.3

Liabilities	
Accounts payable	16.7
Debt	0.9
Accrued comp. & other liab.	17.0
Acquisition pay. & cont. consideration	18.5
Paid-in capital	562.8
Accumulated deficit (net)	(183.6)
Accumulated other comprehensive loss	(6.0)
Total Liabilities / Equity	426.3

2023 // Investor Presentation

OrthOPediatrics 29

Full	Year	2023	Guidance	9
------	------	------	----------	---

2023 Guidance	
	FY2023
Revenue	\$148.0 to \$151.0
Adjusted EBITDA	\$3.0 to \$4.0
	(\$ in Millions, except per share items
Assumptions	
	FY2023
2023 Total Revenue Growth %	21% to 23%
MD Ortho and Pega Medical contribution	\$7.0
Organic Revenue Growth %	15% to 18%
Set Deployment	~\$25
Adjusted EPS <sup>2</sup>	~(\$0.95)
	(\$ in Millions, except per share items
sentation aries	



